title: Renal tolerance of gadolinium-DOTA and gadolinium-DTPA in rats.
abstract: OBJECTIVE
  Although gadolinium chelates are mainly eliminated by the kidney, there is limited information about their effects. The renal tolerance of these compounds on renal function in an in vivo rat model are evaluated.
  
  
  METHODS
  A combination of renal ischemia and intrarenal iodinated contrast agent infusion (diatrizoate) led to a reproducible and reversible model of acute renal failure (n = 5). Using this model, the renal tolerance of gadolinium DOTA (Gd-DOTA) (n = 10) and gadolinium DTPA (Gd-DTPA) (n = 10) were evaluated. The effects of the association of Gd-DOTA with diatrizoate (n = 5) on renal function also were assessed.
  
  
  RESULTS
  Gadolinium DOTA induced no change in serum creatinine and creatinine clearance. Gadolinium DTPA induced a significant increase in serum creatinine (50 to 83 +/- 5 and 70 +/- 6 mumol/L) before and at 24 and 48 hours, respectively (P < .05), and a decrease in creatinine clearance from 1.6 +/- 0.1 to 0.8 +/- 0.1; 1.2 +/- 0.1 mL/mL before and at 24 and 48 hours, respectively (P < .05). In this model, Gd-DOTA did not modify the renal tolerance of diatrizoate as assessed with serum creatinine and creatinine clearance.
  
  
  CONCLUSIONS
  Gadolinium DOTA is not nephrotoxic and can be infused in association with iodinated contrast media. In this model, Gd-DTPA induced reversible renal failure.
authors.affiliation: Department of Nephrology, Hopital Pitié Salpétriére, Paris, France.
authors.forename: G
authors.initials: G
authors.lastname: Brillet
authors.forename: M
authors.initials: M
authors.lastname: Dubois
authors.forename: H
authors.initials: H
authors.lastname: Beaufils
authors.forename: R
authors.initials: R
authors.lastname: Bourbouze
authors.forename: G
authors.initials: G
authors.lastname: Deray
mesh_terms: D058186:Acute Kidney Injury / Q000139:chemically induced*; D000818:Animals; D003287:Contrast Media / Q000009:adverse effects*; D003973:Diatrizoate / Q000009:adverse effects; D019786:Gadolinium DTPA; D006571:Heterocyclic Compounds / Q000009:adverse effects*; D007668:Kidney / Q000187:drug effects*; D008279:Magnetic Resonance Imaging; D008297:Male; D009942:Organometallic Compounds / Q000009:adverse effects*; D004369:Pentetic Acid / Q000009:adverse effects / Q000031:analogs & derivatives*; D051381:Rats; D017207:Rats, Sprague-Dawley
chemical_list: D003287:Contrast Media; D006571:Heterocyclic Compounds; D009942:Organometallic Compounds; D003973:Diatrizoate; D004369:Pentetic Acid; C050823:gadolinium 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetate; D019786:Gadolinium DTPA